Moderna lifts 2026 revenue growth outlook to 15‑25% and reports positive Phase 3 results for intismeran
Moderna announced at its 2026 Analyst Day that it now expects revenue to grow 15%‑25% in 2026, up from a prior outlook of up to 10%. The company also disclosed positive Phase 3 data for its melanoma therapy intismeran, showing a 42% reduction in recurrence risk and a 38% reduction in distant metastasis versus Keytruda alone. Financially, Moderna projected cash costs of about $4 billion in 2027 and $4‑4.5 billion annually through 2030, while targeting roughly $9 billion in total liquidity by year‑end 2026. It also extended its $1.5 billion credit facility to 2031 with a 75‑basis‑point interest‑rate reduction.
Why it matters
The higher revenue growth guidance and expected gross‑margin expansion suggest stronger earnings potential, while the disclosed cash‑cost plan and $9 billion liquidity cushion indicate the company can fund its oncology expansion without immediate financing strain (the company said). Analysts are divided on valuation implications, with some raising price targets and others remaining cautious.
Key facts
- 1Moderna raised its 2026 revenue growth forecast to 15%‑25%, versus the previous outlook of up to 10%. investing.com
- 2The company expects cash costs of approximately $4 billion in 2027. investing.com
- 3Annual cash expenditures are projected to be $4 billion‑$4.5 billion from 2027 through 2030. finance.yahoo.com
- 4Moderna anticipates ending 2026 with about $9 billion in total liquidity. finance.yahoo.com
- 5The $1.5 billion credit facility was extended to 2031, with the interest rate cut by 75 basis points and $900 million borrowing capacity retained through 2029. finance.yahoo.com
- 6Phase 3 results for intismeran autogene (mRNA‑4157/V940) showed a 42% reduction in recurrence or death risk and a 38% reduction in distant metastasis risk versus Keytruda alone. finance.yahoo.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.